The biopharma and drug supply chain sectors outperformed the market last week, even as Trump administration officials pressed the president’s blueprint to lower drug prices, with tough rhetoric for drugmakers and public shaming of pharmaceutical firms for supposedly blocking competition.
“Drug companies have insisted we can have new cures or affordable prices, but not both,” said Health and Human Services Secretary Alex Azar said in a speech Monday.
